Jefferies Group LLC set a €87.00 ($102.35) price target on Sanofi SA (EPA:SAN) in a report released on Thursday. The brokerage currently has a neutral rating on the stock.

A number of other brokerages also recently commented on SAN. Deutsche Bank AG set a €96.00 ($112.94) price target on Sanofi SA and gave the company a buy rating in a report on Tuesday, May 2nd. J P Morgan Chase & Co set a €95.00 ($111.76) price target on Sanofi SA and gave the company a neutral rating in a report on Thursday, June 22nd. UBS AG set a €82.00 ($96.47) price target on Sanofi SA and gave the company a neutral rating in a report on Friday, April 28th. Berenberg Bank set a €97.00 ($114.12) price target on Sanofi SA and gave the company a neutral rating in a report on Saturday, May 20th. Finally, Goldman Sachs Group, Inc. (The) set a €82.00 ($96.47) price target on Sanofi SA and gave the company a neutral rating in a report on Tuesday, May 2nd. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have given a buy rating to the stock. Sanofi SA currently has an average rating of Hold and a consensus target price of €87.44 ($102.87).

Sanofi SA (EPA SAN) traded down 0.17% during mid-day trading on Thursday, reaching €82.10. 1,039,692 shares of the company were exchanged. The stock has a market capitalization of €103.10 billion and a price-to-earnings ratio of 11.45. Sanofi SA has a 1-year low of €62.50 and a 1-year high of €92.97. The stock’s 50-day moving average price is €25.48 and its 200-day moving average price is €25.74.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/25/sanofi-sa-san-given-a-87-00-price-target-at-jefferies-group-llc.html.

Sanofi SA Company Profile

Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company operates in two segments, Pharmaceuticals and Vaccines. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Analyst Recommendations for Sanofi SA (EPA:SAN)

Receive News & Stock Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related stocks with our FREE daily email newsletter.